1. Home
  2. GKOS vs TGS Comparison

GKOS vs TGS Comparison

Compare GKOS & TGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • TGS
  • Stock Information
  • Founded
  • GKOS 1998
  • TGS 1992
  • Country
  • GKOS United States
  • TGS Argentina
  • Employees
  • GKOS 995
  • TGS N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • TGS Natural Gas Distribution
  • Sector
  • GKOS Health Care
  • TGS Utilities
  • Exchange
  • GKOS Nasdaq
  • TGS Nasdaq
  • Market Cap
  • GKOS 5.1B
  • TGS 4.1B
  • IPO Year
  • GKOS 2015
  • TGS N/A
  • Fundamental
  • Price
  • GKOS $90.26
  • TGS $27.40
  • Analyst Decision
  • GKOS Strong Buy
  • TGS Strong Buy
  • Analyst Count
  • GKOS 13
  • TGS 1
  • Target Price
  • GKOS $155.00
  • TGS $35.00
  • AVG Volume (30 Days)
  • GKOS 1.0M
  • TGS 313.5K
  • Earning Date
  • GKOS 04-30-2025
  • TGS 05-05-2025
  • Dividend Yield
  • GKOS N/A
  • TGS N/A
  • EPS Growth
  • GKOS N/A
  • TGS 622.80
  • EPS
  • GKOS N/A
  • TGS 0.48
  • Revenue
  • GKOS $383,481,000.00
  • TGS $1,183,090,354.00
  • Revenue This Year
  • GKOS $27.84
  • TGS N/A
  • Revenue Next Year
  • GKOS $27.99
  • TGS N/A
  • P/E Ratio
  • GKOS N/A
  • TGS $11.32
  • Revenue Growth
  • GKOS 21.85
  • TGS 23.70
  • 52 Week Low
  • GKOS $77.91
  • TGS $14.16
  • 52 Week High
  • GKOS $163.71
  • TGS $34.37
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 41.57
  • TGS 54.99
  • Support Level
  • GKOS $86.16
  • TGS $26.63
  • Resistance Level
  • GKOS $94.55
  • TGS $30.41
  • Average True Range (ATR)
  • GKOS 6.54
  • TGS 1.83
  • MACD
  • GKOS 1.11
  • TGS 0.32
  • Stochastic Oscillator
  • GKOS 54.51
  • TGS 70.14

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About TGS Transportadora de Gas del Sur SA TGS

Transportadora de Gas del Sur SA is a transporters of natural gas in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, and Production and Commercialization Liquids, Other Services, and Telecommunications. It generates maximum revenue from the Production and Commercialization of the Liquids segment. Geographically, it derives the majority of its revenue from Argentina.

Share on Social Networks: